For the quarter ending 2025-09-30, ACXP had -$157,326 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,992,790 | -4,395,472 |
| Share-based compensation | 294,793 | 657,814 |
| Share-based payments to vendors | 45,059 | 196,260 |
| Other receivable | 0 | -10,919 |
| Prepaid expenses | 104,679 | -46,601 |
| Accounts payable and accrued expenses | -123,352 | -238,195 |
| Net cash used in operating activities | -1,880,969 | -3,722,073 |
| Reverse stock split fractional share adjustment | 1,040 | - |
| Proceeds from 2025 warrant exercise, net of issuance costs | 0 | 2,480,553 |
| Proceeds from issuance of common stock in connection with equity line of credit purchase agreement, net of issuance costs | 1,724,683 | 610,262 |
| Proceeds from 2025 march registered direct offering, net of issuance costs | 0 | 889,420 |
| Proceeds from 2025 january registered direct offering, net of issuance costs | 0 | 2,099,253 |
| Net cash provided by financing activities | 1,723,643 | 6,079,488 |
| Net increase/(decrease) in cash | -157,326 | 2,357,415 |
| Cash and cash equivalents at beginning of period | 3,706,713 | - |
| Cash and cash equivalents at end of period | 5,906,802 | - |
Acurx Pharmaceuticals, Inc. (ACXP)
Acurx Pharmaceuticals, Inc. (ACXP)